CVRx
Yahoo Finance • last year
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • last year
CMS Increases Outpatient Payment for Barostim Procedure
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant proce... Full story
Yahoo Finance • last year
CVRx Reports Third Quarter 2023 Financial and Operating Results
MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • last year
CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • last year
CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • last year
CVRx Set to Join Russell 2000 & 3000 Indexes
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CVRx Reports First Quarter 2023 Financial and Operating Results
MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neu... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NYSE: CVRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomla... Full story
Yahoo Finance • 2 years ago
10 High Growth Micro-Cap Stocks to Buy According to Hedge Funds
In this article, we will look at 10 high growth micro-cap stocks to buy according to hedge funds. If you want to explore similar stocks, you can also take a look at 5 High Growth Micro-Cap Stocks to Buy According to Hedge Funds. Investing... Full story
Yahoo Finance • 2 years ago
CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial
MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation dev... Full story
Yahoo Finance • 2 years ago
CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CVRx Launches new Barostim NEO2™ Implantable Pulse Generator
The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, In... Full story
Yahoo Finance • 2 years ago
CVRx Launches a new Barostim™ Programmer
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which... Full story
Yahoo Finance • 3 years ago
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to... Full story
Yahoo Finance • 3 years ago
CVRx Reports First Quarter 2022 Financial and Operating Results
MINNEAPOLIS, April 25, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
